Biomphalaria occidentalis sp.n. from South America (Mollusca basommatophora pulmonata)

A new species of South American planorbid snail, Biomphalaria occidentalis, is described. It is indistinguishable from B. tenagophila (Orbigny, 1835), by the characteristics of the shell and of most organs of the genital system. In B. tenagophila there is a pouch on the ventral wall of the vagina (Fig. 4A, vp), absent in B. occidentalis (Fig. 3A), and on the ventral wall of the vagina (Fig. 4A, vp), absent in B. occidentalis (Fig. 3A), and the prepuce is much wider than the penial sheath, its width increasing distalward (Fig. 4, ps,pp), whereas in B. occidentalis the prepuce is wider than the penial sheath but keeps about the same width all along (Fig.3, ps, pp). The two species are biologically separate by absolute reproductive isolation. The geographical distribution of B. occidentalis is shown in Fig. 14. So far it has been found in the Brazilian states of Acre, Amazonas (?), Mato Grosso, Mato Grosso do Sul and Paraná, and in Paraguay. Its type-locality is Campo Grande, state of Mato Grosso do sul, where it was collected from several biotopes related to affluents of the Aquiduana river, chiefly Córrego Prosa and Córrego Ceroula. Specimens were deposited in the following malacological collections: Instituto Oswaldo Cruz, Rio de Janeiro; Academy of Natural Sciences, Philadelphia; Museum of Zoology, University of Michigan; and British Museum (Natural History).

Lymnaea rupestris sp. n. from Southern Brazil (Pulmonata: Lymnaeidae)

A new species of South American lymnaeid snail, Lymnaea rupestris, is described. So far it has been found only in its type-locality, Nova TeuTõnia, a village in the municipality of Seara (27° 07' S, 52° 17' W), state of Santa Catarina, Brazil. It is distinguishable, by characteristics of the shell and internal organs, from the other two lymnaeid species known to occur in the area, Lymnaea columella and L. viatrix. Its shell has 4 markedly shouldered whorls, deep suture, ovoid or rounded aperture occupying about half the length of the shell, and reaches about 6 mm in length in adults; in columella and viatrix the shell has 4-5 rounded whorls, shallow suture, and reaches over 10 mm in adults; the aperture is ovoid, occupying about half the length of the shell in viatrix, about two thirds in columella. Anatomically it is readily separated from L. columella by the shape of the ureter, straight in rupestris, with a double flexure in columella. Comparison with L. viatrix shows the following main differences: distalmost portion of the oviduct with a low, caplike lateral swelling in rupestris, with a well-developed pouch in viatrix; uterus bent abruptly caudalward in rupestris, only slightly curved rightward in viatrix; basal half of the spermathecal duct hidden by the prostate in rupestris, wholly visible or nearly so in viatrix; spermiduct sinuous and uniformly wide in rupestris, straight and gradually narrowing in viatrix; prostate more than half as long and nearly as wide as the nidamental gland, and with a slit-like lumen in cross-section in rupestris, less than half as long as and much narrower than the nidamental gland, and with an inward fold in cross-section in viatrix; penial sheath about as long and as wide as the prepuce in rupesris, shorter and narrower than the prepuce in viatrix. An important ecological characteristic of L. rupestris is its habitat on wet rocks most often outside bodies of water, although in close proximity to them. Specimens were deposited in the following malacological collections: Instituto OswaldoCruz, Rio de Janeiro; Academy of Natural Sciences, Philadelphia; Museum of Zoology, University of Michigan; and British Museum (Natural History).

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia

Chronic myeloid leukemia (CML) is rare in the pediatric population, accounting for 2-3% of childhood leukemia cases, with an annual incidence of one case per million children. The low toxicity profile of imatinib mesylate has led to its approval as a front-line therapy in children for whom interferon treatment has failed or who have relapsed after allogeneic transplantation. We describe the positive responses of 2 children (case 1 - from a 7-year-old male since May 2005; case 2 - from a 5-year-old female since June 2006) with Philadelphia-positive chromosome CML treated with imatinib (300 mg/day, orally) for up to 28 months, as evaluated by morphological, cytogenetic, and molecular approaches. Our patients are alive, are in the chronic phase, and are in continuous morphological complete remission.